Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NVCR – NovoCure Limited

NovoCure Limited
NVCR
$11.32
Name : NovoCure Limited
Sector : Healthcare
Industry: Medical Devices
Mark. Cap: $1,265,564,672.00
EPSttm : -1.56
finviz dynamic chart for NVCR
NovoCure Limited
$11.32
2.16%
$0.25

Float Short %

4.97

Margin Of Safety %

Put/Call OI Ratio

0.13

EPS Next Q Diff

-0.13

EPS Last/This Y

-0.02

EPS This/Next Y

-0.13

Price

11.32

Target Price

27.19

Analyst Recom

1.75

Performance Q

-36.94

Relative Volume

1.38

Beta

0.61

Ticker: NVCR




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04NVCR17.710.120.0820658
2025-07-07NVCR16.890.120.0820737
2025-07-08NVCR17.510.120.2620820
2025-07-09NVCR18.20.120.2920885
2025-07-10NVCR18.470.120.3020943
2025-07-11NVCR17.60.120.2520946
2025-07-14NVCR17.430.120.0620960
2025-07-15NVCR16.770.120.0820955
2025-07-16NVCR16.580.120.0121089
2025-07-17NVCR16.190.120.3121424
2025-07-18NVCR16.020.111.7221635
2025-07-21NVCR16.180.100.0919594
2025-07-22NVCR16.30.100.0120005
2025-07-23NVCR16.50.100.1520361
2025-07-24NVCR12.540.100.5220962
2025-07-25NVCR12.030.130.1623363
2025-07-28NVCR11.650.130.5524239
2025-07-29NVCR11.380.120.1424284
2025-07-30NVCR10.980.130.2025704
2025-07-31NVCR11.570.130.0726716
2025-08-01NVCR11.320.130.1527510
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04NVCR17.71-25.8-80.2-1.65
2025-07-07NVCR16.89-25.8-71.9-1.65
2025-07-08NVCR17.51-25.8-90.6-1.65
2025-07-09NVCR18.19-25.8-91.2-1.65
2025-07-10NVCR18.46-25.8-85.6-1.65
2025-07-11NVCR17.60-25.8-75.1-1.65
2025-07-14NVCR17.42-25.8-80.1-1.65
2025-07-15NVCR16.79-25.8-74.2-1.65
2025-07-16NVCR16.58-25.8-79.4-1.65
2025-07-17NVCR16.21-25.8-77.1-1.65
2025-07-18NVCR16.01-25.8-79.5-1.65
2025-07-21NVCR16.11-25.8-83.6-1.65
2025-07-22NVCR16.30-25.8-85.1-1.65
2025-07-23NVCR16.51-25.8-85.3-1.65
2025-07-24NVCR12.54-25.8-27.4-1.65
2025-07-25NVCR12.04-25.8-73.0-1.64
2025-07-28NVCR11.64-25.3-67.8-1.58
2025-07-29NVCR11.38-51.0-49.3-1.58
2025-07-30NVCR10.97-51.0-47.3-1.58
2025-07-31NVCR11.57-51.0-66.5-1.58
2025-08-01NVCR11.32-51.0-50.2-1.58
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04NVCR-0.654.095.01
2025-07-07NVCR-0.654.095.01
2025-07-08NVCR-0.654.095.01
2025-07-09NVCR-0.654.095.01
2025-07-10NVCR-0.654.095.01
2025-07-11NVCR-0.654.095.29
2025-07-14NVCR-0.654.175.29
2025-07-15NVCR-0.654.175.29
2025-07-16NVCR-0.644.175.29
2025-07-17NVCR-0.644.175.29
2025-07-18NVCR-0.644.175.29
2025-07-21NVCR-0.644.165.29
2025-07-22NVCR-0.644.165.29
2025-07-23NVCR-0.644.165.29
2025-07-24NVCR-0.644.165.29
2025-07-25NVCR-0.644.164.99
2025-07-28NVCR-0.643.974.97
2025-07-29NVCR-0.643.974.97
2025-07-30NVCR-0.483.974.97
2025-07-31NVCR-0.483.974.97
2025-08-01NVCR-0.483.974.97
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.36

Avg. EPS Est. Current Quarter

-0.42

Avg. EPS Est. Next Quarter

-0.49

Insider Transactions

-0.48

Institutional Transactions

3.97

Beta

0.61

Average Sales Estimate Current Quarter

158

Average Sales Estimate Next Quarter

160

Fair Value

Quality Score

29

Growth Score

39

Sentiment Score

23

Actual DrawDown %

95.1

Max Drawdown 5-Year %

-95.1

Target Price

27.19

P/E

Forward P/E

PEG

P/S

2.01

P/B

3.62

P/Free Cash Flow

EPS

-1.56

Average EPS Est. Cur. Y​

-1.58

EPS Next Y. (Est.)

-1.71

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-27.13

Relative Volume

1.38

Return on Equity vs Sector %

-72.7

Return on Equity vs Industry %

-67.2

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.07

EBIT Estimation

-50.2
NovoCure Limited
Sector: Healthcare
Industry: Medical Devices
Employees: 1488
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
stock quote shares NVCR – NovoCure Limited Stock Price stock today
news today NVCR – NovoCure Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch NVCR – NovoCure Limited yahoo finance google finance
stock history NVCR – NovoCure Limited invest stock market
stock prices NVCR premarket after hours
ticker NVCR fair value insiders trading